📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-29 18:19
9 analysed today
FollowTelegram
9
Today
150,918
All-time analysed
43,225
Positive
6,714
Negative
92,195
Neutral
8,716
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
20 announcements match the current filters (relevance ≥ 5).
Hexagon Nutrition Completes Commercial Process Validation for Food Fortification Product 'VIT A+'
Hexagon Nutrition Limited and Particles for Humanity have successfully completed the commercial-scale process validation of PFH-VAP. The product, a stable formulation of Vitamin A Palmitate intended for large-scale food fortification, is proposed to be marketed internationally under the brand name 'VIT A+'. While this validates the manufacturing feasibility at scale, financial details, expected revenue, and capex were not disclosed in the filing. In the recent quarter ending June 2026, Hexagon reported revenue of Rs 104.31 crore and net profit of Rs 8.07 crore.
Confidence: HIGH
What changedHexagon Nutrition validated the commercial manufacturing process of PFH-VAP, advancing it from development to preparation for commercial launch under the brand 'VIT A+'.
Why it mattersProves manufacturing feasibility for a specialized food fortification product targeted at export markets, potentially expanding high-margin international revenues.
Quarterly Revenue (Jun 2026): Rs 104.306 crQuarterly Net Profit (Jun 2026): Rs 8.073 crExpected commercial launch date: not disclosedEstimated market size / Capex: not disclosed
📅 Short termPositive sentiment from technical and scale validation, though immediate financial impact is limited until commercial supply commences.
📈 Long termCould open new international B2B and institutional revenue streams in the large-scale food fortification vertical if commercial adoption is successful.
⚠ Risk flags
- Commercialization timeline and financial terms with partner Particles for Humanity not disclosed
- Commercial uptake remains subject to international regulatory approvals and customer adoption
Key Highlights
Completed commercial-scale process validation of PFH-VAP with partner Particles for Humanity on September 29, 2026
Product is a stable formulation of Vitamin A Palmitate intended for large-scale food fortification
Proposed to be marketed commercially under the brand name 'VIT A+' in international markets
Hexagon reported Q1 Jun 2026 revenue of Rs 104.306 crore and net profit of Rs 8.073 crore
👀 What to Watch
Track the timeline for commercial rollout, regulatory approvals across target export markets, and eventual revenue contribution from international sales of VIT A+.
Hexagon Nutrition Chairman & ED Arun Kelkar Steps Down Effective September 28, 2026
Hexagon Nutrition Limited announced that its Chairman & Executive Director, Arun Purushottam Kelkar, has completed his tenure and stepped down effective September 28, 2026, at the close of office hours. Kelkar has led the company since its incorporation. The company reported revenue of Rs 104.31 crore and net profit of Rs 8.07 crore in the June 2026 quarter. Investors should monitor subsequent filings regarding leadership succession and board reconstitution.
Confidence: HIGH
What changedArun Kelkar ceased to be Chairman & Executive Director upon completion of his tenure on September 28, 2026.
Why it mattersA transition in top leadership can influence future corporate strategy and operational direction, though this appears to be a scheduled tenure completion.
Date of Cessation: 28 September 2026Jun 2026 Revenue: Rs 104.306 crJun 2026 PAT: Rs 8.073 cr
📅 Short termLimited operational disruption expected as the exit is due to completion of term, though market will look for details on succession.
📈 Long termThe incoming Chairman/executive leadership will determine strategic priorities in the packaged foods and nutrition segments.
⚠ Risk flags
- Leadership transition risk following departure of a founding leader
Key Highlights
Cessation of Arun Purushottam Kelkar as Chairman & Executive Director effective September 28, 2026
Change occurred due to the completion of his scheduled term
Company posted revenue of Rs 104.306 crore and net profit of Rs 8.073 crore in Q1 FY27 (Jun 2026)
👀 What to Watch
Track board announcements regarding the appointment of a new Chairman or executive leadership changes and strategy continuity.
Hexagon Nutrition Chairman & ED Arun Kelkar Steps Down Effective September 28, 2026
Hexagon Nutrition Limited announced that its Chairman & Executive Director, Arun Purushottam Kelkar, has completed his tenure and stepped down effective September 28, 2026, at the close of office hours. Kelkar has led the company since its incorporation. The company reported revenue of Rs 104.31 crore and net profit of Rs 8.07 crore in the June 2026 quarter. Investors should monitor subsequent filings regarding leadership succession and board reconstitution.
Confidence: HIGH
What changedArun Kelkar ceased to be Chairman & Executive Director upon completion of his tenure on September 28, 2026.
Why it mattersA transition in top leadership can influence future corporate strategy and operational direction, though this appears to be a scheduled tenure completion.
Date of Cessation: 28 September 2026Jun 2026 Revenue: Rs 104.306 crJun 2026 PAT: Rs 8.073 cr
📅 Short termLimited operational disruption expected as the exit is due to completion of term, though market will look for details on succession.
📈 Long termThe incoming Chairman/executive leadership will determine strategic priorities in the packaged foods and nutrition segments.
⚠ Risk flags
- Leadership transition risk following departure of a founding leader
Key Highlights
Cessation of Arun Purushottam Kelkar as Chairman & Executive Director effective September 28, 2026
Change occurred due to the completion of his scheduled term
Company posted revenue of Rs 104.306 crore and net profit of Rs 8.073 crore in Q1 FY27 (Jun 2026)
👀 What to Watch
Track board announcements regarding the appointment of a new Chairman or executive leadership changes and strategy continuity.
Hexagon Nutrition Seeks Legal Opinion After Promoters Abstain From Resolution Voting
Hexagon Nutrition Limited reported an update regarding voting outcomes on certain shareholder resolutions, disclosing that Promoter shareholders had abstained from voting. The company is actively seeking an independent legal opinion to decide on the appropriate course of action under applicable law. Further details on the specific resolutions or financial implications were not disclosed in the filing. Investors should note this development follows the company's June 2026 quarterly net profit of Rs 8.073 cr on revenue of Rs 104.306 cr.
Confidence: MEDIUM
What changedPromoters abstained from voting on specific corporate resolutions, prompting the company to seek external legal counsel.
Why it mattersPromoter abstention on key resolutions can signal governance complexities, related-party issues, or strategic disagreements, potentially delaying corporate approvals.
Announcement Date: September 23, 2026June 2026 Quarterly Revenue: Rs 104.306 crJune 2026 Net Profit: Rs 8.073 cr
📅 Short termShort-term uncertainty could persist until the company discloses the specific resolutions involved and the legal counsel's recommendation.
📈 Long termCorporate governance clarity and promoter alignment will be key to avoiding operational or regulatory roadblocks in future resolutions.
⚠ Risk flags
- Uncertainty around the validity or approval of the underlying resolutions
- Potential governance or compliance issues leading to the legal review
Key Highlights
Promoter shareholders abstained from voting on certain resolutions as of September 23, 2026
Company is currently seeking an independent legal opinion to determine next steps
Hexagon Nutrition reported June 2026 quarterly revenue of Rs 104.306 cr and net profit of Rs 8.073 cr
Specific resolution details and voting percentage breakdowns were not disclosed
👀 What to Watch
Track subsequent exchange filings regarding the legal opinion outcome and clarity on which shareholder resolutions were affected.
Hexagon Nutrition AGM: Shareholders Reject Remuneration & Re-appointment of Key Promoters
At Hexagon Nutrition's 33rd Annual General Meeting held on September 22, 2026, public shareholders pushed back on executive compensation and leadership continuity. Three special resolutions failed to pass: Resolution 7 (remuneration of Chairman Arun Kelkar), Resolution 8 (remuneration of MD Vikram Kelkar), and Resolution 11 (re-appointment of Arun Kelkar as Chairman & Executive Director), all receiving 60.86% votes against from voting members. However, routine items including adoption of FY26 financial statements, dividend declaration, and revision of Joint MD Dr. Nikhil Kelkar's remuneration were approved.
Confidence: HIGH
What changedShareholders formally rejected the re-appointment and remuneration of Chairman Arun Kelkar and the remuneration hike for MD Vikram Kelkar.
Why it mattersThe rejection of key promoter executive resolutions signals significant institutional or public shareholder dissent on corporate governance and executive pay structure.
Votes against Chairman re-appointment: 60.86%Votes against MD remuneration revision: 60.86%Total voting shares polled on Resolution 11: 4055160Total shareholders on record date (15-09-2026): 22335
📅 Short termHeightened scrutiny on the board's corporate governance stance and potential overhang until the leadership status of Chairman Arun Kelkar is resolved.
📈 Long termStrong pushback from non-promoter shareholders typically leads to better-aligned executive compensation and improved board independence over time.
⚠ Risk flags
- Shareholder-promoter friction regarding executive remuneration
- Leadership uncertainty following the failed re-appointment of the Chairman
Key Highlights
Resolution 7 (remuneration of Chairman Arun Kelkar) rejected with 60.86% votes cast against (2,468,131 votes against vs 1,587,029 in favour)
Resolution 8 (remuneration of MD Vikram Kelkar) rejected with 60.86% votes cast against (2,468,131 votes against vs 1,587,009 in favour)
Resolution 11 (re-appointment of Arun Kelkar as Chairman & Executive Director) defeated with 60.86% votes against
Resolution 9 (remuneration revision for Joint MD Dr. Nikhil Kelkar) passed with near-unanimous approval (4,054,824 votes in favour)
Resolution 3 approving dividend declaration for FY 2025-26 passed with 100% of votes polled in favour
👀 What to Watch
Track subsequent board notifications regarding governance adjustments, executive leadership succession, or revised compensation proposals following the rejection of the Chairman's re-appointment.
Q1 FY27 Call Transcript: Revenue Up 43.2% to ₹104.3 Cr; MRP Hiked 10-15% to Offset Margin Headwinds
Hexagon Nutrition released the transcript of its Q1 FY27 earnings conference call following its recent June 2026 listing. Consolidated revenue grew 43.2% YoY to ₹104.3 crore (up from ₹72.9 crore), with PAT rising 25.1% YoY to ₹8.1 crore. EBITDA increased at a slower pace of 17.3% YoY to ₹11.8 crore due to raw material inflation and elevated freight costs from geopolitical tensions in West Asia. Segment growth was led by Premix (+55% YoY), ESG (+42% YoY), and Branded nutrition (+22% YoY). To protect profitability, the company implemented a 10% to 15% price hike and expanded its sales field force by over 50% YoY.
Confidence: HIGH
What changedFiling of the full transcript of the Q1 FY27 earnings conference call held on August 14, 2026.
Why it mattersProvides detail on how management plans to protect EBITDA margins against freight/raw material pressures through price hikes and sales force expansion.
Q1 FY27 Revenue: INR 104.3 croresQ1 FY27 Revenue Growth (YoY): 43.2%Q1 FY27 PAT: INR 8.1 croreMRP Price Hike: 10% to 15%Field Force Expansion: >50%
📅 Short termEarnings details are already in the market; short-term attention will focus on margin stabilization post-price hikes.
📈 Long termBroadening product penetration in clinical nutrition and export diversification across 70+ countries support long-term scalability.
⚠ Risk flags
- Gross margin compression from raw material price volatility
- Geopolitical freight cost pressures linked to West Asia
- Lag in sales productivity from the >50% surge in field force headcount
Key Highlights
Q1 FY27 consolidated revenue rose 43.2% YoY to ₹104.3 crore compared to ₹72.9 crore in Q1 FY26
EBITDA grew 17.3% YoY to ₹11.8 crore while PAT increased 25.1% YoY to ₹8.1 crore
Segment-wise growth: Premix jumped 55%, ESG expanded 42%, and Branded business grew 22% YoY
Implemented MRP increases of 10% to 15% to offset gross margin pressure over the next two quarters
Field force increased by >50% YoY, with management expecting operating leverage to kick in by end of Q3 FY27
👀 What to Watch
Track whether the 10-15% price hikes successfully restore gross margins in Q2-Q3 FY27 and assess productivity gains from the expanded field force.
₹104.3 Cr Q1 Revenue: Hexagon Nutrition Outlines Growth Strategy in Q1 FY27 Presentation
Hexagon Nutrition reported Q1 FY27 revenue of ₹104.3 cr with an EBITDA margin of 11.3% and PAT of ₹8.1 cr. Following its June 2026 listing, the company is focusing on its B2C clinical nutrition segment (Pentasure) and its B2B2C premix business. The company operates four manufacturing plants across India and Uzbekistan, though capacity utilization remains low in certain segments like Uzbekistan (3.3%). Management is targeting the ₹1.3 trillion Indian nutrition market, which is projected to grow at a 13% CAGR through 2030.
Confidence: HIGH
What changedThis is the first comprehensive investor presentation following the company's June 2026 listing, detailing its Q1 FY27 financial performance and business model.
Why it mattersIt provides transparency into the company's revenue mix and operational efficiency across its clinical, wellness, and humanitarian nutrition segments.
Q1 FY27 Revenue: ₹104.3 crEBITDA Margin: 11.3%PAT Margin: 7.7%R&D Pipeline Products: 9Export Markets: 80+
📅 Short termThe stock may react to the 11.3% EBITDA margin as investors benchmark this newly listed player against established FMCG and nutrition peers.
📈 Long termStructural growth depends on the company's ability to scale its B2C brands (Pentasure, Pediagold) and capitalize on the 12.1% projected CAGR in the clinical nutrition market.
⚠ Risk flags
- Low capacity utilization in Uzbekistan (3.3%) and Thoothukudi (18.9%)
- High dependence on hospital and dietitian recommendations for B2C sales
Key Highlights
Reported Q1 FY27 Revenue of ₹1,043 Mn (₹104.3 cr) with a PAT of ₹81 Mn.
EBITDA margin for the quarter stood at 11.3% on an EBITDA of ₹118 Mn.
Maintains a distribution network of 358 domestic and 20 international distributors.
B2C segment features 12+ clinical SKUs under the flagship brand Pentasure.
Manufacturing footprint includes 4 plants with a total of 527+ permanent staff.
👀 What to Watch
Monitor capacity utilization improvements at the Thoothukudi (18.9%) and Uzbekistan (3.3%) plants, as higher throughput is essential for margin expansion.
43.2% Revenue Growth in Q1 FY27; PAT up 25.1% to ₹8.1 Cr in First Post-IPO Results
Hexagon Nutrition reported a strong 43.2% YoY revenue growth to ₹104.3 crore for Q1 FY27, marking its first quarterly disclosure since its June 2026 IPO. While the top-line showed robust momentum, EBITDA margins contracted by 250 basis points to 11.3% compared to 13.8% in the previous year's quarter. Consequently, EBITDA growth of 17.3% lagged behind revenue growth. Profit After Tax (PAT) increased by 25.1% to ₹8.1 crore, supported by the company's diversified presence across 70+ countries.
Confidence: HIGH
What changedThis is the first financial performance report issued by Hexagon Nutrition as a publicly listed entity following its IPO in June 2026.
Why it mattersIt establishes a performance baseline for the company as a listed entity, demonstrating strong demand for its micronutrient and clinical nutrition products despite margin pressures.
Revenue (Q1 FY27): ₹104.3 croreRevenue Growth (YoY): 43.2%PAT (Q1 FY27): ₹8.1 croreEBITDA Margin: 11.3%Margin Compression: 250 bpsBasic EPS: ₹0.67
📅 Short termThe strong top-line growth is likely to be viewed positively by the market, though the 250 bps margin contraction may lead to some caution regarding cost management.
📈 Long termThe company is positioned in the high-growth nutrition and fortification segment; long-term value depends on scaling its international presence and maintaining operational efficiency.
⚠ Risk flags
- EBITDA margin compression of 250 bps YoY
- Potential raw material price volatility affecting gross margins
- Execution risks in diverse international markets
Key Highlights
Revenue from operations increased 43.2% YoY to ₹104.3 crore from ₹72.9 crore.
Profit After Tax (PAT) grew 25.1% YoY to ₹8.1 crore with a PAT margin of 7.7%.
EBITDA margins compressed by 250 bps YoY to 11.3% from 13.8%.
Gross Profit rose 34.1% YoY to ₹45.8 crore.
The company maintains a global footprint across 70+ countries with 4 manufacturing facilities.
👀 What to Watch
Investors should monitor the company's ability to stabilize EBITDA margins back toward the FY26 level of 13.8% and track the scaling of international operations which currently span 70+ countries.
Hexagon Nutrition Recommends ₹0.30 Dividend and Re-appoints Chairman
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per equity share (30% of face value) for FY26, with a record date of September 15, 2026. The company approved its Q1 FY27 financial results and scheduled its 33rd Annual General Meeting for September 22, 2026. Key management decisions include the re-appointment of Arun Purushottam Kelkar as Chairman and the appointment of Raghunath Sawant as an Additional Executive Director. The board also approved revisions to the remuneration of promoter-directors, subject to shareholder approval.
Confidence: HIGH
What changedThe company has declared its final dividend for the previous fiscal year, updated its board composition with a new executive director, and initiated the process for re-appointing its Chairman.
Why it mattersThe announcement confirms management continuity and provides a clear timeline for dividend payouts, which is a key return metric for shareholders in the packaged foods sector.
Final Dividend: ₹0.30 per shareFace Value: ₹1 per shareRecord Date: September 15, 2026AGM Date: September 22, 2026
📅 Short termThe stock may see some interest leading up to the dividend record date of September 15, 2026.
📈 Long termLeadership continuity is maintained through the re-appointment of the Chairman; however, the impact of increased director remuneration on net margins should be monitored.
⚠ Risk flags
- Remuneration revisions for three promoter-directors (Kelkar family) may impact profitability if not aligned with growth
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26
Fixed September 15, 2026, as the Record Date for dividend eligibility
Scheduled the 33rd Annual General Meeting (AGM) for September 22, 2026
Appointed Raghunath Sawant as Additional Executive Director effective August 12, 2026
Approved the dissolution of the IPO Committee following the successful completion of the IPO
👀 What to Watch
Investors should review the Q1 FY27 financial performance once the full results are published and monitor the details of the proposed remuneration revisions for promoter-directors in the upcoming AGM notice.
Hexagon Nutrition Recommends ₹0.30 Dividend; Sets AGM for Sept 22, 2026
Hexagon Nutrition has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with a record date of September 15, 2026. The board approved Q1 FY27 financial results and scheduled the 33rd AGM for September 22, 2026. Key leadership decisions include the re-appointment of Chairman Arun Kelkar for a 5-year term and the appointment of Raghunath Sawant as an Additional Executive Director. The company also dissolved its IPO committee following successful completion of its listing process.
Confidence: HIGH
What changedThe company has transitioned out of its IPO phase by dissolving the IPO committee and has established its dividend and leadership roadmap for the next five years.
Why it mattersThe dividend recommendation signals a commitment to shareholder returns, while the 5-year re-appointment of the Chairman ensures leadership stability for the newly listed entity.
Final Dividend: ₹0.30 per shareFace Value: ₹1Record Date: September 15, 2026AGM Date: September 22, 2026Chairman Re-appointment Term: 5 years
📅 Short termThe stock may see interest leading up to the dividend record date in mid-September; however, the primary driver will be the Q1 FY27 earnings performance.
📈 Long termLeadership continuity and the cleanup of the Articles of Association (removing VC-specific clauses) indicate a maturing corporate governance structure post-listing.
⚠ Risk flags
- Revision in promoter-director remuneration requires shareholder approval
- Removal of specific clauses in Articles of Association
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26.
Fixed September 15, 2026, as the record date for dividend eligibility.
Re-appointed Arun Purushottam Kelkar as Chairman for a 5-year term starting September 28, 2026.
Appointed Raghunath Sawant as Additional Executive Director effective August 12, 2026.
Proposed alteration of Articles of Association to remove references to Malani Ventures Private Limited.
👀 What to Watch
Investors should review the detailed Q1 FY27 financial results and monitor the shareholder vote on the proposed revision of Director remuneration at the upcoming AGM.
₹0.30 Dividend Declared; Hexagon Nutrition Re-appoints Chairman for 5-Year Term
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per equity share (30% of face value) for FY26, with the record date set for September 15, 2026. The company approved the re-appointment of promoter Arun Purushottam Kelkar as Chairman and Executive Director for a five-year term starting September 28, 2026. Additionally, Raghunath Sawant was appointed as an Additional Executive Director for five years. The board also approved the dissolution of the IPO Committee following the successful completion of its listing process.
Confidence: HIGH
What changedThe company has formalized its post-IPO board structure, re-confirmed promoter leadership for five years, and initiated its first post-listing dividend cycle.
Why it mattersLeadership continuity under the Kelkar family remains intact, while the dissolution of the IPO committee and AoA amendments (removing references to Malani Ventures) signal a transition to a standard listed entity structure.
Final Dividend: ₹0.30 per shareDividend Record Date: September 15, 2026Chairman Re-appointment Term: 5 yearsAGM Date: September 22, 2026Face Value: ₹1
📅 Short termThe stock may see mild interest leading up to the dividend record date in mid-September; Q1 results will drive immediate price action.
📈 Long termThe 5-year re-appointment of the Chairman ensures strategic continuity in the packaged foods/nutrition segment.
⚠ Risk flags
- Remuneration revisions for promoter-directors require shareholder approval at the AGM.
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26.
Fixed September 15, 2026, as the Record Date for dividend eligibility.
Re-appointed Arun Purushottam Kelkar as Chairman for a 5-year term starting September 28, 2026.
Appointed Raghunath Sawant as Additional Executive Director for a 5-year term effective August 12, 2026.
Scheduled the 33rd Annual General Meeting (AGM) for September 22, 2026.
👀 What to Watch
Investors should track the Q1 FY27 financial results for growth trends and note the September 15 record date for dividend eligibility.
Hexagon Nutrition Recommends ₹0.30 Dividend and Appoints New Executive Director
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per equity share (30% of face value) for FY26, with a record date of September 15, 2026. The company appointed Mr. Raghunath Sawant as an Additional Executive Director for a 5-year term and recommended the re-appointment of Chairman Arun Purushottam Kelkar for another 5 years. The board also approved Q1 FY27 financial results and dissolved the IPO Committee following the successful completion of its listing. Additionally, the Articles of Association are being amended to remove references to Malani Ventures Private Limited.
Confidence: HIGH
What changedThe company has formalized its post-IPO governance structure by dissolving the IPO committee, appointing a new Executive Director, and proposing a dividend payout for the previous fiscal year.
Why it mattersThese administrative and leadership updates ensure management continuity for the next five years and provide a baseline for shareholder returns through dividends.
Final Dividend: ₹0.30 per shareDividend Record Date: September 15, 2026AGM Date: September 22, 2026Director Appointment Term: 5 yearsFace Value: ₹1 per share
📅 Short termThe stock may see minor interest leading up to the September 15 record date for the dividend; however, the primary driver will be the Q1 FY27 earnings performance.
📈 Long termLeadership stability is reinforced by the 5-year re-appointment of the Chairman and the promotion of a long-term employee to the board.
⚠ Risk flags
- Proposed revision in remuneration for promoter-directors (Chairman, MD, and JMD) requires shareholder scrutiny.
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26.
Fixed September 15, 2026, as the Record Date for dividend eligibility.
Appointed Mr. Raghunath Sawant as Additional Executive Director for a 5-year term effective August 12, 2026.
Recommended re-appointment of Chairman Arun Purushottam Kelkar for a 5-year term starting September 28, 2026.
Dissolved the IPO Committee with immediate effect following the successful completion of the IPO.
👀 What to Watch
Investors should review the full Q1 FY27 financial results once published and monitor the upcoming AGM on September 22, 2026, for approval of the dividend and director appointments.
Hexagon Nutrition Recommends ₹0.30 Dividend, Appoints New Director, and Amends AOA
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per equity share (30% of face value) for FY26, with a record date of September 15, 2026. The company is also undergoing management changes, including the appointment of Raghunath Sawant as an Additional Executive Director and the re-appointment of Chairman Arun Kelkar for a 5-year term. A significant governance update involves amending the Articles of Association to remove references to Malani Ventures Private Limited and deleting Part B entirely, signaling a post-IPO cleanup. The 33rd Annual General Meeting is scheduled for September 22, 2026.
Confidence: HIGH
What changedThe company is formalizing its post-IPO governance by dissolving the IPO committee and removing specific investor-related clauses from its Articles of Association.
Why it mattersThese changes simplify the corporate structure and ensure management continuity, while the dividend provides a modest yield to shareholders.
Final Dividend: ₹0.30 per shareFace Value: ₹1Record Date: September 15, 2026AGM Date: September 22, 2026Director Appointment Term: 5 years
📅 Short termThe stock may see minor activity around the record date for the dividend; however, the primary driver will be the Q1 FY27 financial performance details.
📈 Long termThe removal of venture capital-specific clauses from the AOA indicates a transition to a standard public company governance model, which is structurally positive.
⚠ Risk flags
- Revision in promoter-director remuneration requires shareholder approval at the AGM.
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26.
Fixed September 15, 2026, as the record date for dividend eligibility.
Appointed Raghunath Sawant as Additional Executive Director for a 5-year term effective August 12, 2026.
Re-appointed Arun Purushottam Kelkar as Chairman for a 5-year term starting September 28, 2026.
Proposed deletion of Part B of the Articles of Association and removal of references to Malani Ventures Private Limited.
👀 What to Watch
Investors should review the Q1 FY27 financial results (approved in this meeting) and monitor the approval of director remuneration revisions at the upcoming AGM on September 22, 2026.
₹0.30 Final Dividend Recommended; Record Date Fixed for Sept 15, 2026
Hexagon Nutrition has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with the record date set for September 15, 2026. The board also approved the unaudited financial results for Q1 FY27 and scheduled the 33rd AGM for September 22, 2026. Key management updates include the re-appointment of Chairman Arun Kelkar for a 5-year term and the appointment of Raghunath Sawant as an Additional Executive Director. Additionally, the company is amending its Articles of Association to remove references to Malani Ventures and has dissolved its IPO committee following the successful listing.
Confidence: HIGH
What changedThe company has formalized its first post-IPO dividend, updated its leadership structure, and initiated a cleanup of its Articles of Association by removing legacy investor references.
Why it mattersThe dividend recommendation signals management's intent to share profits with shareholders, while the 5-year re-appointment of the Chairman ensures leadership continuity in the post-listing phase.
Final Dividend: ₹0.30 per shareFace Value: ₹1Record Date: September 15, 2026AGM Date: September 22, 2026Chairman Tenure: 5 years
📅 Short termThe stock may see neutral to positive movement as investors react to the dividend announcement and the Q1 FY27 earnings performance.
📈 Long termThe dissolution of the IPO committee and removal of legacy clauses in the AoA indicate the company is maturing into its status as a public entity with stable promoter leadership.
⚠ Risk flags
- Revision in promoter-director remuneration (subject to shareholder approval)
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for FY26.
Fixed September 15, 2026, as the Record Date for dividend eligibility.
Re-appointed Chairman Arun Purushottam Kelkar for a 5-year term effective September 28, 2026.
Appointed Raghunath Sawant as Additional Executive Director effective August 12, 2026.
Scheduled the 33rd Annual General Meeting (AGM) for September 22, 2026.
👀 What to Watch
Investors should review the Q1 FY27 financial results once fully published to assess growth trends and monitor the AGM for approval of the dividend and revised director remuneration.
₹0.30 Dividend Recommended; Hexagon Nutrition Appoints New Director and Dissolves IPO Committee
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with a record date of September 15, 2026. The company is transitioning to a post-IPO structure, evidenced by the dissolution of its IPO Committee and the removal of specific investor rights (Malani Ventures) from its Articles of Association. Management changes include the appointment of Raghunath Sawant as Additional Executive Director and a proposed revision in remuneration for the promoter-directors. The 33rd Annual General Meeting is scheduled for September 22, 2026.
Confidence: HIGH
What changedThe company has formalized its dividend payout timeline, updated its board composition, and cleaned up its Articles of Association by removing pre-IPO investor references.
Why it mattersThese actions signal the company's normalization as a listed entity and provide a direct cash return to shareholders, while management changes indicate a shift in governance structure.
Final Dividend: ₹0.30 per shareFace Value: ₹1Record Date: September 15, 2026AGM Date: September 22, 2026Director Appointment Term: 5 years
📅 Short termThe stock may experience minor price adjustments around the dividend record date of September 15, 2026.
📈 Long termLimited structural impact; the changes reflect standard corporate governance and administrative updates for a newly listed company.
⚠ Risk flags
- Revision in promoter-director remuneration requires shareholder scrutiny regarding performance alignment.
Key Highlights
Recommended a final dividend of ₹0.30 per equity share of face value ₹1 for the financial year ended March 31, 2026.
Fixed September 15, 2026, as the Record Date for dividend eligibility.
Appointed Raghunath Sawant as Additional Executive Director for a 5-year term effective August 12, 2026.
Dissolved the IPO Committee with immediate effect following the successful completion of the IPO.
Proposed alteration of Articles of Association to remove references to Malani Ventures Private Limited.
👀 What to Watch
Investors should review the Q1 FY27 financial results once published in full and monitor the proposed increase in promoter-director remuneration at the upcoming AGM on September 22, 2026.
₹66 Cr Bank Facilities Assigned 'CARE A-; Stable' Rating; Agency Changed to CARE
Hexagon Nutrition Limited has transitioned its credit rating mandate from ICRA Limited to CARE Ratings Limited. CARE has assigned a 'CARE A-; Stable' rating for ₹23 crore in long-term bank facilities and a dual 'CARE A-; Stable / CARE A2+' rating for ₹43 crore in long/short-term facilities. The total rated debt of ₹66 crore includes ₹18.03 crore in proposed term loans, indicating potential future borrowing. This rating reflects the agency's independent assessment of the company's financial and operational profile as of late July 2026.
Confidence: HIGH
What changedThe company has replaced ICRA Limited with CARE Ratings Limited as its credit rating agency and received fresh ratings for its bank facilities.
Why it mattersA credit rating of 'A-' signifies a low risk of default and provides transparency regarding the company's ability to service its ₹66 crore debt, which is critical for maintaining banking relationships and managing interest costs.
Total Rated Facilities: ₹66.00 croreLong Term Rating: CARE A-; StableShort Term Rating: CARE A2+Proposed Term Loans: ₹18.03 croreRating Date: July 29, 2026
📅 Short termThe announcement is administrative and likely to have a neutral impact on the stock price in the immediate term.
📈 Long termThe 'Stable' outlook suggests the company is expected to maintain its financial profile over the next year; structural significance is limited unless the proposed loans lead to major capex.
⚠ Risk flags
- Potential volatility if rating-related trigger clauses are introduced in bank facility terms.
Key Highlights
Total bank facilities rated by CARE Ratings amount to ₹66.00 crore.
Long-term facilities of ₹23.00 crore assigned a 'CARE A-; Stable' rating.
Combined long-term/short-term facilities of ₹43.00 crore assigned 'CARE A-; Stable / CARE A2+'.
The rating includes ₹18.03 crore in proposed term loans and ₹4.97 crore in existing Citi Bank loans.
Rating is valid for one year from the initial communication date of July 28, 2026.
👀 What to Watch
Investors should monitor the utilization of the ₹18.03 crore proposed term loans to see if they are directed toward capacity expansion. The 'A-' rating indicates a stable credit profile, but any future change in this rating could impact the company's borrowing costs.
Hexagon Nutrition FY26 Earnings Call: Receivables Rise to ₹82 Cr Amid 15-20% Growth Target
Hexagon Nutrition conducted its maiden earnings call post-listing, highlighting a diversified portfolio across clinical nutrition and food fortification. Trade receivables increased to ₹82 crore in FY26 from ₹60 crore in FY25, attributed to large ESG and domestic premix orders dispatched in the final quarters. Management expressed confidence in maintaining a historical growth trajectory of 15-20% for FY27, despite geopolitical tensions in West Asia. The company is focusing on expanding its brands PediaGold and Obesigo into Tier 2 and Tier 3 cities to compete with global players.
Confidence: HIGH
What changedThis filing provides the first detailed management commentary post-listing, clarifying segment-wise performance and addressing concerns regarding rising receivables.
Why it mattersIt establishes the company's growth guidance (15-20%) and reveals the management's strategy to penetrate deeper into the Indian clinical nutrition market beyond Tier 1 cities.
Trade Receivables (FY26): ₹82 croreTrade Receivables (FY25): ₹60 croreTarget Growth Rate: 15%-20%Earnings Call Date: July 17, 2026
📅 Short termThe stock may see neutral to slightly cautious sentiment as investors digest the increase in trade receivables despite the positive growth outlook.
📈 Long termThe company is positioned in a structural growth industry (preventive healthcare) with a focus on high-margin clinical nutrition, which could drive value if execution in Tier 2/3 cities succeeds.
⚠ Risk flags
- Elongated receivable cycle due to large ESG and domestic orders
- High competition in clinical nutrition from global majors like Abbott
Key Highlights
Trade receivables increased by 36.6% to ₹82 crore in FY26 from ₹60 crore in the previous year.
Management targets a consistent revenue growth rate of 15%-20% for the upcoming financial year.
The company operates two key manufacturing facilities in Nashik, Maharashtra and Chennai, Tamil Nadu.
The earnings call held on July 17, 2026, marked the company's first interaction with investors post-listing.
Management identified PentaSure as the lead brand, with plans to scale PediaGold and Obesigo in FY27.
👀 What to Watch
Monitor the normalization of trade receivables in the H1FY27 results to ensure working capital cycles are stabilizing as management suggested.
Hexagon Nutrition Discloses ₹13.31 Cr Net Liability in Overseas Subsidiaries
Hexagon Nutrition has issued a comprehensive clarification to its Prospectus, correcting several administrative and financial disclosures. The most significant update reveals that its South African and Uzbekistan subsidiaries carry a combined net liability of ₹133.15 million as of December 31, 2025, due to historical losses. While these units turned a profit of ₹20.94 million in the current period, they remain dependent on an unconditional financial guarantee from the parent company to continue operations. Additionally, the company redefined its Chief Operating Decision Maker (CODM) from the CFO to the Managing Director.
Confidence: HIGH
What changedThe company revised its Prospectus to include specific 'going concern' justifications for overseas units and corrected various auditor and management designations.
Why it mattersThis filing provides a more transparent view of the financial risks in international operations, specifically the reliance of certain subsidiaries on parent company funding to meet liabilities.
Net liability (Overseas units): ₹133.15 millionCurrent period profit (Overseas units): ₹20.94 millionReporting date for liabilities: December 31, 2025Number of subsidiaries clarified: 6
📅 Short termThe market may react cautiously to the formal disclosure of net liabilities and the material uncertainty regarding future cash flows in overseas markets.
📈 Long termThe structural health of the company depends on these international units becoming self-sustaining and reducing their reliance on the parent company's financial guarantees.
⚠ Risk flags
- Material uncertainty regarding future cash flows in regional markets
- Reliance on parent company for unconditional financial support
- Historical accumulated losses in overseas subsidiaries
Key Highlights
Disclosed a net liability position of ₹133.15 million for subsidiaries in South Africa and Uzbekistan as of Dec 31, 2025
Reported a combined operational recovery profit of ₹20.94 million for these overseas units in the current period
Reassigned the Chief Operating Decision Maker (CODM) role from the CFO to the Managing Director
Corrected auditor details and examination periods for subsidiaries in China, South Africa, and Uzbekistan
Updated segment reporting to include 'ESG' alongside Premix and Brand within the Nutraceuticals segment
👀 What to Watch
Investors should monitor the quarterly performance of the South African and Uzbekistan subsidiaries to verify if the recent ₹20.94 million profit is a sustainable trend or a one-off recovery.
₹3,826 Mn FY26 Revenue: Hexagon Nutrition Reports 13.8% EBITDA Margin and 20.9% ROCE
Hexagon Nutrition Limited reported a strong FY26 performance with revenue reaching ₹3,826 Mn, reflecting a 13.4% CAGR since FY24. Profitability showed significant improvement, with EBITDA margins expanding from 6.2% in FY24 to 13.82% in FY26, and PAT margins reaching 9.9%. The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.13x and a high ROCE of 20.9%. Exports remain a dominant revenue driver, contributing 57% (₹2,163 Mn) of total sales across 80+ countries.
Confidence: HIGH
What changedThe company released its first comprehensive investor presentation post-listing, detailing full-year FY26 financial performance and operational metrics.
Why it mattersThe results demonstrate significant operating leverage, with margins expanding rapidly as the company scales its integrated nutrition platform across 80+ countries while remaining nearly debt-free.
FY26 Revenue: ₹3,826 MnEBITDA Margin: 13.82%Export Revenue Share: 57%Debt-to-Equity Ratio: 0.13xROCE: 20.9%Net Debt: ₹(145) Mn
📅 Short termThe stock may see positive sentiment as the market reacts to the strong margin expansion and high ROCE figures disclosed in this post-listing presentation.
📈 Long termThe company is well-positioned in the high-growth nutraceutical sector with a diversified portfolio and a strong global footprint, suggesting sustainable long-term growth potential.
⚠ Risk flags
- High dependence on export markets (57% of revenue)
- Raw material price volatility (24% of materials are imported)
Key Highlights
Revenue grew to ₹3,826 Mn in FY26, achieving a 13.4% CAGR over the FY24-FY26 period
EBITDA margin more than doubled from 6.2% in FY24 to 13.82% in FY26
PAT CAGR stood at a high 76.2% between FY24 and FY26, with FY26 PAT margin at 9.9%
Export revenue contributed ₹2,163 Mn, representing 57% of the total FY26 revenue mix
Return on Capital Employed (ROCE) improved sharply to 20.9% in FY26 from 5.9% in FY24
👀 What to Watch
Investors should monitor the growth of the B2C clinical nutrition segment (Pentasure brand) and the operational ramp-up of the Uzbekistan manufacturing facility for international market penetration.
1 Executive Director Resigns: Subhash Purushottam Kelkar departs Hexagon Nutrition
Hexagon Nutrition Limited has announced the resignation of Mr. Subhash Purushottam Kelkar from his position as Executive Director. The resignation became effective on July 6, 2026. As an Executive Director, Mr. Kelkar was part of the company's senior leadership team. The company has not disclosed the reason for his departure or a successor in this specific filing.
Confidence: HIGH
What changedMr. Subhash Purushottam Kelkar has stepped down from his role as Executive Director of Hexagon Nutrition Limited.
Why it mattersThe resignation of an Executive Director impacts the board's composition and potentially the oversight of specific business functions.
Effective Date: July 6, 2026Filing Date: July 7, 2026
📅 Short termThe stock may see neutral movement as the market awaits details on the successor and the impact on operations.
📈 Long termLimited structural significance unless this marks a broader shift in the company's leadership strategy or governance.
Key Highlights
Resignation of 1 Executive Director, Mr. Subhash Purushottam Kelkar
Effective date of the resignation is July 6, 2026
The official intimation was signed on July 7, 2026
👀 What to Watch
Monitor future filings for the appointment of a new Executive Director to understand the company's leadership transition plan.
